Healios KK (JP:4593)
:4593
4593 Stock Chart & Stats
¥402.00
¥3.00(1.60%)
At close: 4:00 PM EST
¥402.00
¥3.00(1.60%)
Day’s Range― - ―
52-Week Range¥194.00 - ¥747.00
Previous CloseN/A
Volume811.70K
Average Volume (3M)1.65M
Market Cap
¥54.27B
Enterprise Value¥39.57B
Total Cash (Recent Filing)¥5.68B
Total Debt (Recent Filing)¥2.61B
Price to Earnings (P/E)―
Beta1.03
Next Earnings
May 20, 2026EPS Estimate
-10.98Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)18.90
Shares Outstanding135,002,200
10 Day Avg. Volume1,843,110
30 Day Avg. Volume1,654,023
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.03
Price to Sales (P/S)283.63
P/FCF Ratio-8.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥1,130.00Price Target Upside181.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-42.73
Revenue Forecast (FY)¥658.52M
Bulls Say, Bears Say
Bulls Say
Focused Regenerative Medicine PlatformHealios’s specialization in cell-based therapies (ophthalmology, CNS) and use of somatic stem cells/iPSC creates durable technical know‑how and clinical expertise. This focused platform plus external collaborations supports a long-term pathway to commercialization and IP differentiation that can compound over multiple development cycles.
Improving LeverageA meaningful decline in debt-to-equity reduces near-term refinancing pressure and improves financial flexibility, important for a capital-intensive biotech. Lower leverage lengthens runway and allows management to prioritize R&D and clinical milestones without immediate liquidity strain, strengthening resilience over months.
Consistent Modest Revenue GrowthSequential revenue growth, though modest, indicates emerging commercial traction or recurring revenue streams. For a small biotech, steady top-line gains provide evidence of product or service market fit and can support incremental scaling, reduce reliance on financing over time if growth continues and margins improve.
Bears Say
Deep, Worsening UnprofitabilityNegative gross profit and persistently heavy operating and net losses indicate the business is not yet self-sustaining. Structural unprofitability erodes equity and limits reinvestment capacity, making the company reliant on external financing and increasing execution risk over the medium term absent major commercial or cost breakthroughs.
Persistent Negative Cash FlowMaterially negative operating and free cash flows, with worsening cash burn, reduce the firm’s runway and raise the likelihood of future capital raises. For a development‑stage biotech with multi‑year trials, ongoing cash burn is a structural vulnerability that can force dilutive financing or delay programs if cash flow does not improve.
Weak Operating Leverage And High Cost BaseHigh fixed costs relative to a small revenue base mean additional sales may not quickly drive profitability. Weak operating leverage lengthens time to break‑even, increases sensitivity to funding availability, and makes the business model structurally dependent on either rapid scale or sustained external financing to reach self-sufficiency.
Healios KK News
4593 FAQ
What was Healios KK’s price range in the past 12 months?
Healios KK lowest stock price was ¥194.00 and its highest was ¥747.00 in the past 12 months.
What is Healios KK’s market cap?
Healios KK’s market cap is ¥54.27B.
When is Healios KK’s upcoming earnings report date?
Healios KK’s upcoming earnings report date is May 20, 2026 which is in 47 days.
How were Healios KK’s earnings last quarter?
Healios KK released its earnings results on Feb 16, 2026. The company reported ¥18.9 earnings per share for the quarter, beating the consensus estimate of ¥4.65 by ¥14.25.
Is Healios KK overvalued?
According to Wall Street analysts Healios KK’s price is currently Undervalued.
Does Healios KK pay dividends?
Healios KK does not currently pay dividends.
What is Healios KK’s EPS estimate?
Healios KK’s EPS estimate is -10.98.
How many shares outstanding does Healios KK have?
Healios KK has 135,002,200 shares outstanding.
What happened to Healios KK’s price movement after its last earnings report?
Healios KK reported an EPS of ¥18.9 in its last earnings report, beating expectations of ¥4.65. Following the earnings report the stock price went up 4.087%.
Which hedge fund is a major shareholder of Healios KK?
Currently, no hedge funds are holding shares in JP:4593
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Healios KK
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company is also developing cellular and tissue-based products comprising HLCR011 and HLCR012 that are iPSC regenerative medicines for the treatment of age-related macular degeneration; HLCL041, an iPSC regenerative medicine for the treatment of metabolic liver disease; and HLCM051, a regenerative medicine for treatment of ischemic stroke and acute respiratory distress syndrome, as well as HLCN061 for treating solid tumors. Healios K.K. has a joint research agreement with the Hyogo Medical University on cancer immunotherapies for mesothelioma using eNK cells. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
4593 Stock 12 Month Forecast
Average Price Target
¥1,130.00
▲(181.09% Upside)
Technical Analysis
SanBio Co
―
StemRIM Inc.
―
ReproCELL Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---